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Abstract
Candida albicans, the most common human pathogenic fungus, can establish a persistent lethal infection in the intestine of
the microscopic nematode Caenorhabditis elegans. The C. elegans–C. albicans infection model was previously adapted to
screen for antifungal compounds. Modifications to this screen have been made to facilitate a high-throughput assay
including co-inoculation of nematodes with C. albicans and instrumentation allowing precise dispensing of worms into
assay wells, eliminating two labor-intensive steps. This high-throughput method was utilized to screen a library of 3,228
compounds represented by 1,948 bioactive compounds and 1,280 small molecules derived via diversity-oriented synthesis.
Nineteen compounds were identified that conferred an increase in C. elegans survival, including most known antifungal
compounds within the chemical library. In addition to seven clinically used antifungal compounds, twelve compounds were
identified which are not primarily used as antifungal agents, including three immunosuppressive drugs. This assay also
allowed the assessment of the relative minimal inhibitory concentration, the effective concentration in vivo, and the toxicity
of the compound in a single assay.
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Introduction
The soil dwelling nematode Caenorhabditis elegans has become a
model host to study mammalian virulence of both bacterial and
fungal pathogens [1,2], including Candida albicans, the most
commonly isolated fungal pathogen from blood cultures [3].
Importantly, key components of Candida pathogenesis in mam-
mals, such as biofilm and filament formation, are also involved in
nematode killing [2]. Because of these features, assays have been
devised that involve killing of C. elegans by fungal pathogens which
can be used to screen fungal mutants for virulence factors and
libraries of compounds for antifungal activity [4–6].
Use of a whole animal assay during antifungal screens provides
several advantages when compared to more commonly used
inhibitory compound screens that are preformed in vitro. First, the
immunomodulatory affect of the compound on the host immune
system can be assessed in the presence of a pathogen. Additionally,
effective compounds that function by inhibiting pathogen
virulence factors can be identified, as some of these factors are
only expressed in a host. Another important advantage of using a
model host during screening is that it allows simultaneous
assessment of toxicity. Frequently, compounds toxic to fungi also
have undesirable effects on the mammalian host. This toxicity/
efficacy ‘‘bottleneck’’ delays antifungal drug discovery.
C. elegans whole-animal screens in particular have several
advantages over other mammalian screening models. The C.
elegans model does not raise as many ethical concerns as the use of
vertebrate models. Moreover, nematodes are easy to manipulate in
the laboratory because they are small enough to fit into standard
96- and 384-well microtiter plates and they have short and simple
reproductive cycles. C. elegans worms are also relatively inexpensive
to propagate in large numbers and are genetically tractable [7–9].
The two main objectives of this paper are to first develop an
automated, high-throughput, C. elegans assay that can be used to
screen chemical compounds in vivo, and second use this new assay
to identify chemicals with antifungal activity.
Methods
Media and strains
C. albicans strain DAY185 [10], which was used in all assays, was
grown overnight to late-log phase with shaking at 30uC in yeast
extract peptone dextrose (YPD) (Difco) medium containing the
antibiotics kanamycin (45 mg/ml), ampicillin (100 mg/ml), and
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PBS and re-suspended at a concentration of 2.5610
5 cells/ml.
A C. elegans glp-4;sek-1 double mutant was used in all assays. The
glp-4(bn2) mutation renders the strain incapable of producing
progeny at 25uC [11] and the sek-1(km4) mutation causes
enhanced sensitivity to various pathogens [12], thereby decreasing
assay time. Nematodes were grown on nematode growth medium
(NGM) with Escherichia coli strain HB101 as the food source as
previously described [6,13]. Screen medium was 30% brain heart
infusion medium (BHI, Difco) in M9 buffer [13] containing
antibiotics kanamycin (90 mg/ml), ampicillin (200 mg/ml), and
streptomycin (200 mg/ml). M9 buffer was used to wash the worms
as needed and for diluting screen media.
Z9-factor values
Positive and negative control data were used to calculate
the Z9-factor as a measure of overall assay quality [14].
Z9=12((3sc++3sc2)/(|mc+2mc2|)), where mc+ and mc2 are the
averages of test sample signals for both the positive and negative
controls respectively, and sc+ and sc2 are the variations in signal
measurements for the positive and negative controls respectively.
Dimethyl sulfoxide (DMSO, 2%) in the screen medium served as
the negative control, and amphotericin B and ketoconazole in
screen medium were used individually as positive antifungal
controls. Concentrations of the antifungal agents used were
effective against the C. albicans DAY185 strain used for the assay.
Two columns (16 wells) in each 96-well plates were used for each
concentration of the antifungal. Z9-factor values were calculated
for each of the antifungal agents.
C. elegans–C. albicans assay
The pre-infection assay was performed as previously described
[6]. In brief, worms grown on NGM plates were washed with M9
buffer and placed on 48 h-old C. albicans lawns (on BHI agar
plates) for 2 h. The worms were washed off the plates using screen
medium, transferred to two separate beakers, and re-suspended at
a density of 1–2 worm/ml in screen medium. Twenty ml of the
suspension of pre-infected worms were added to wells of 96-well
non-binding half area plates (Corning) containing 80 ml of screen
medium. The details concerning the addition of compounds to the
wells are stated below in the following text. Plates were sealed with
Breathe-Easy
TM membranes (Diversified Biotech), and incubated
at 25uC for 96 h. The survival rates of both exposed and
unexposed worms were analyzed using the STATA 6 software.
The procedures for the co-inoculation assay were similar to
those of the pre-infection assay above with the following
modifications [15]: 70 ml of screen medium was dispensed into
each well of a 96-well non-binding half area plate (Corning) using
a MultiDrop Combi Plate Filler (Thermo Scientific) equipped with
a standard dispensing cassette (Thermo Scientific). When
compounds were used, approximately 450 nl of each compound
was pin-transferred from compound plates into individual wells
(containing 70 ml of screen medium) of 96-well assay plates
simultaneously with a 96-pin head (CyBi
H-Well, CyBio). Worms
were grown and washed as in the pre-infection assay, except that
they were not previously infected with C. albicans. A Union
Biometrica COPAS-BIOSORT
TM worm sorter was used to
dispense automatically 15+/21 worms into each well, followed
by addition of 10 mlo faC. albicans suspension at a density of
2.5610
5 cells/ml in PBS with a Multidrop Combi Plate Filler.
Acquisition and analysis of data for co-inoculation assay
At the end the incubation period, the plates were imaged using
the Molecular Devices Discovery-1 microscope (MDS Analytical
Technologies) running MetaExpress software by capturing
transmitted light images. Images of the entire well were captured
using a 26low magnification objective lens. Prior to analysis, the
images were converted from 16 bit TIF files to 8 bit JPEG files
using the CellProfiler
TM image analysis software [16,17]. The
resulting images were visually analyzed for in vitro fungal growth,
followed by visually scoring of live and dead worms based on
nematode shape, as live worms appear sinusoidal and dead worms
are rod shaped.
The determination of the lowest concentration of the selected
compounds showing in vitro antifungal activity was accomplished
by following the steps detailed in the co-inoculation assay, using
two-fold serial dilutions of the test compounds. The wells were
assessed by visually monitoring the turbidity for concentrations
exhibiting in vitro inhibition of C. albicans growth. A quantitative
scoring system was developed to measure and rank the activity of
hits. For this, compounds of interest were tested in a series of two-
fold dilutions, and the half maximum effective concentrations
(EC50) which conferred 50% survival of the worms was
determined.
Results/Discussion
Optimization of the C. albicans–C. elegans assay for high-
throughput use
Previous work has demonstrated that C. elegans can serve as a
host for Candida spp. and an infection is established in the worm
intestine when nematodes are fed on a lawn of C. albicans on agar
medium [6]. Using this pathosystem, a C. elegans-C. albicans
‘‘curing’’ assay was developed using liquid media in standard 96-
well plates which allowed simultaneous assessment of both the
compound’s antifungal activity and the compound’s cellular
toxicity. This relatively low-throughput assay entailed pre-
infection of the nematodes, by placing them on a C. albicans lawn
on BHI agar plates prior to the assay, followed by manually
pipetting the infected worms into microtiter plates containing the
compounds to be screened.
One of the goals of the current work was to increase the
throughput of the chemical screening assay by utilizing a
commercial instrument to distribute a precise number of infected
worms in each microtiter well. However, the use of the instrument
to dispense Candida-infected nematodes was not practical, as the
fungus formed avid biofilms on the surface of the instrument such
that it could not be efficiently decontaminated after each use. To
circumvent this problem, direct C. albicans infection of the worms
by co-inoculation in assay wells containing the liquid medium was
assessed. The survival of worms pre-exposed to C. albicans lawns on
agar before transferring to the assay medium was compared to
worm survival when the nematode and C. albicans were co-
inoculated in the assay medium. The rate of worm survival was
comparable in the co-inoculation and pre-infection assays
(Figure 1), demonstrating that prior exposure of the nematodes
to C. albicans on solid media is not necessary for killing of the
nematodes. The killing of worms may commence sooner when
worms are pre-infected for two hours before transferring to assay
wells, but by four days there was no significant difference between
the two treatments, as all of the worms were dead in both
instances. Additionally, there was no difference in the frequency
and amount of filamention by C. albicans in dead worms in either
assay (data not shown).
Several concentrations of fungal inoculum (10
2 to 10
5 cells/well)
were examined, and a concentration 2.5610
3 cells/well was
optimal for the 96 hour assay period, which resulted in a killing
rate comparable to the pre-infection assay (data not shown).
Antifungal Bioactive Compounds
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in wells with high turbidity that required a washing step prior to
imaging in order to score the assay results. Fifteen worms per well
of the 96-well half area plate was optimal for the assay, as wells
with more than 15 worms per well caused the worms to overlap in
the confined area making it more difficult to score whether the
nematodes were alive or dead based on shape.
In the C. elegans-C. albicans antifungal discovery assay detailed in
Breger et al (2007) [6], preinfection of the worms requires not only
additional time to allow ingestion and subsequent colonization of
the nematode intestinal tract, but also additional resources such as
premade plates with lawns of C. albicans for the infection and
materials to recollect the worms post-inoculation. This improved
assay also cuts time by dispensing a precise number of worms by
instrumentation instead of manual pipetting. As worms are
manually pipetted they begin to settle at the bottom of the tube
where they are held, creating a ‘‘gradient’’ of various worm
densities where the top portion of the liquid contains a lower
density of worms when compared to the bottom of the tube. This
gradient leads to various amounts for worms being pipetted into
each well, and thus creates situations where the assay for a
compound may need to be repeated due to either too few or too
many nematodes within each well. Therefore this improved assay
not only saves several hours when setting up the assay, but may
save several weeks as some compounds would not have to be
repeated by additional screening.
Evaluation of the co-inoculation assay
In order to evaluate the reproducibility and robustness of the co-
infection assay the Z9-factor was determined. This calculation
takes into account signals from both positive and background
samples and is used to assess the probability that a sample scored
as positive in a screen is genuine and not due to background noise
[14]. For this evaluation, the percentage of worm survival was used
in calculations after the following treatments: dimethyl sulfoxide
(DMSO) was used as a negative control (background), and
amphotericin B (2.5 mg/ml) and ketoconazole (16.0 mg/ml),
(which conferred 93–100% worm survival) were used as the
positive controls. In three independent experiments during assay
development, the Z9 factor values were reproducible for each of
the compound concentrations, ranging from 0.69 to 0.72, with an
average value of 0.71.
Similar to the pre-infection assay, wells that contained no
antifungal, compounds without antifungal efficacy, or antifungal
compounds at a concentration below the effective dose result in
rod-shaped dead worms with fungal filaments protruding from
their cuticles (Figures 2A–2D). Interestingly, growth of C. albicans
within the liquid medium was not necessary for nematode death,
as filaments of C. albicans were seen extruding from some dead
nematodes despite no in vitro growth, suggesting the compound
inhibited the fungus in vitro but not in vivo. This observation was
made in control assay wells, as treatment with 1 mg/ml of
amphotericin B exhibited antifungal activity in vitro, but not in vivo
(Figure 2C) as well as compounds identified in the screen
(Figure 2D). However, in wells with effective antifungal agents at
inhibitory concentrations, the worms maintain their sinusoidal
shape, and the media remained free of fungal growth. This
observation was made in both control assay wells with amphoter-
icin B and well containing screened antifungal compounds
exhibiting both in vitro and in vivo activities (Figure 2E and 2F).
During the preliminary screen of the compound library, wells
that displayed a reduction or no in vitro fungal growth, however
had little or no nematode survival, were counted and potential
antifungal compounds. Upon confirmatory experiments, the
compounds were able to confer nematode survival at higher
concentrations than initially tested in the preliminary screening
process. Therefore, all identified compounds conferred in vitro and
in vivo antifungal activity. There were no compounds identified in
the screen which conferred C. elegans survival in the presence of in
vitro fungal growth, an observation which would suggest that the
compound may have 1) an immunomodulatory effect on the
nematode immune response, and/or 2) properties which inhibit
pathogen specific virulence factor(s). Despite not finding any
compounds which inhibit C. albicans in vivo but not in vitro, we feel it
is possible to do so using this assay as the concentration of fungal
cells initially inoculated to the wells still enables the visualization of
the nematodes at the conclusion of the screen.
Of note is that in previous studies the scoring of live/dead and
worms with and without filaments was accomplished by direct
microscopic observation of movement and morphology of the
nematodes. In these assays, digital images from the Discovery-1
microscope were captured and visually inspected for the analysis of
assay results. This method improved the accuracy of analysis and
evaluation of the assay, and moved the process closer to an
automated ‘‘screening by imaging’’ system. Recently, SYTOX
Orange live/dead staining has been utilized to facilitate high-
throughput scoring of C. elegans survival [18], although the same
approach may not necessarily be feasible for C. albicans due to
background resulting from staining of live hyphal filaments
extending from the dead nematode. Alternatively, imaging
programs that can differentiate between nematode shapes can
also possibly be developed to facilitate scoring of nematode
survival at the conclusion of the screen [16,17,19].
Identification of antifungal compounds resulting from
the screen
After establishing the robustness and repeatability of the assay, a
screen of 3,228 compounds was conducted representing com-
pounds not screened in previous studies. This study, in
combination with the previous screen by Breger et al (2007),
brings the total number of screened compounds to 4,494. This
collection was represented by 1,948 bioactive compounds
consisting of FDA approved drugs and other compounds from
the Microscorce Spectrum collection (Microsource Discovery
Systems, Inc.) and the Prestwick compound library (Prestwick
Chemicals, Inc.) and 1,280 small molecules derived via diversity-
Figure 1. Comparison of inoculation procedures. Comparison of
nematode survival between worms co-inoculated with C. albicans
during compound exposure, and worms pre-infected with the fungus
prior to compound exposure.
doi:10.1371/journal.pone.0007025.g001
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MIT (Cambridge, MA). As shown in Table 1, the screening library
represented a diverse collection of bioactive compounds composed
of multiple chemical classes containing a broad array of
functionality. In total, 19 compounds were identified in the screen
(Figure 3). More importantly, the C. elegans screen was able to
detect most of the well established antifungal agents (Table 1 and
Table 2).
Of the ten antimycotic compounds within the chemical library,
all but three (flutrimazole, thiabendazole, and griseofulvin) were
identified in the preliminary screen. All three of these compounds
are used in topical treatment of fungal infections, and may have
limited solubility in water, complicating their identification using
the C. elegans-C. albicans ‘‘curing’’ assay. Furthermore, griseofulvin
has no antifungal activity against Candida spp., as the fungus does
not uptake the compound into the fungal cell, and therefore it
would not be expected to be identified [22]. The compound
thiabendazole is used agriculturally as a fungicide and has been
used clinically in treatment of Aspergillus flavus [23,24], however it is
also nematocidial [25]. Several other antinematode compounds
were represented in the chemical library including the clinically
relevant agent albendazole and the avermectin, abamectin. These
compounds exemplify three scenarios where a potential antifungal
agent would be overlooked in the C. elegans-C. albicans antifungal
discovery assay; 1) if the compound has limited solubility in water,
2) if the assayed compound has antifungal activity, as well as
nematicidal activity, and 3) if the compound has activity against
most fungi, although the fungus used in the screen (C. albicans)
maybe unaffected by the compound.
A number of known immuno-modulating agents were found to
have antifungal activity in the C. elegans killing assay. This group
includes FK-506, ascomycin, and cyclosporin A, all of which have
previously been reported to have antifungal activity not only for C.
albicans, but also other fungal pathogens such as Cryptococcus
neoformans, Aspergillus fumigatus, and members of the zygomycetes
[26–32]. These immunosupressives demonstrated weak antifungal
activity when compared to clinically relevant antifungal agents,
however they were able to confer ,50% nematode survival at the
Figure 2. Representative assay wells from the C. elegans-C. albicans antifungal compound screen. (A) Negative control (DMSO added); (C)
and (E) Amphothericin B was added as a positive control at either 1.0 mg/mL (C) or 2.5 mg/mL (E); (B,D,F) Screened compound (in this case
ketoconazole) exhibiting no antifungal activity (2 mg/mL; (B)), in vitro antifungal activity (4 mg/mL; (D)), and in vivo antifungal activity conferring C.
elegans survival (8 mg/mL (F).
doi:10.1371/journal.pone.0007025.g002
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therapeutic drugs, calcineurin, is essential for virulence of C.
albicans and is involved in a diverse array of other pathogenicity
factors, including the ability to survive in serum and resistance to
antifungal azole compounds [27–29]. The antifungal activity of
these immunosuppressives, coupled with their ability to impede
azole resistance, create (at least in vitro) a synergistic effect when
used with clinically relevant antifungal agents [33,34]. This
synergism has been observed for many fungal pathogens, including
azole resistant C. albicans isolates [31–33,35]. Importantly,
immunotherapy with calcineurin inhibitors does not select for C.
albicans strains which are resistant to these compounds [36].
Among the hits was the potential promising compound
dequalinium chloride which is a potent anti-tumor and protein
kinase C (PKC) inhibitor (Figure 4B). In Saccharomyces cerevisiae, the
Rho 1-PKC pathway (the cell integrity pathway) functions in cell
wall biosynthesis and mating [5,37,38]; cell wall integrity is
involved in C. elegans killing by fungi [5]. Another compound,
triadimefon, also conferred a similar degree of nematode survival
(Figure 4B). The fungicide triadimefon has no affect on DNA,
RNA, or protein synthesis, and instead derives it antifungal activity
by inhibiting ergosterol biosynthesis [39]. The potent H
+ V-
ATPase inhibitor concanamycin A was also identified, although it
had been previously described as having antifungal properties
[40]. This compound demonstrated the highest antifungal activity
outside of the clinically used antifungal agents in the screen
(Table 2 and Figure 4B). However, concanamycin A is highly
toxic, limiting its use clinically. Mice injected with 1 mg per
kilogram body mass interperitoneally die [40], however no toxicity
was observed at the highest concentration tested (1.4 mg/mL).
Determination of MIC and EC50 of compounds
Dose response curves were determined to calculate the minimal
inhibitory concentration (MIC) and the effective dose that resulted
in 50% survival of the nematodes (EC50) for 18 compounds
identified in the screen that prevented growth of C. albicans in vitro
(Table 2). The EC50 for most of the compounds was usually twice
the MIC concentration, with a few exceptions. In this assay the
Table 1. Compounds exhibiting antifungal activity identified in the C. elegans–C. albicans infection assay.
Compound Action/Use Reference(s)
Currently used antifungal agents
Amphotericin B Interacts with ergosterol to form transmembrane channels [47,48]
Nystatin Binds to ergosterol to produce permeability changes [49]
Ketoconazole Interferes with synthesis of ergosterol [50]
Terconazole Interferes with synthesis of ergosterol [51]
Bifonazole Interferes with synthesis of ergosterol [50]
Butoconazole nitrate Interferes with synthesis of ergosterol [52,53]
Oxiconazole nitrate Interferes with synthesis of ergosterol [52,54]
Immunosuppressant agents
Ascomycin Ethyl analogue of FK-506; binds to immunophilins, inhibits production of Th1 and Th2 cytokines [55]
FK-506 (Tacrolimus) Forms a complex with FKBP-12 to inhibit calcineurin [56]
Cyclosporin A Forms a complex with cyclophilin to inhibit calcineurin [57]
Other compounds
Triadimefon Affects gibberellin and sterol biosynthesis [39]
Dequalinium chloride Potent anti-tumor activity and protein kinase C alpha (PKC) inhibitor [58]
Valinomycin Apoptosis inducer by disrupting mitochondrial membrane potential; affects morphology of C. albicans [59–61]
Phenylmercuric acetate Used as fungicide, herbicide, slimicide and bacteriocide; metabolized to diphenylmercury [62]
Malachite green carbinol base Malachite green is used to treat parasites, fungal, and bacterial infections in fish and fish eggs; metabolized
to the carbinol form and then to the toxic leucomalachite green form.
[42,63]
Concanamycin A Potent and specific inhibitor of vacuolar-ATPase [40]
Ellipticine Potent anti-tumor agent, acts by DNA intercalation and/or inhibition of topoisomerase II [64]
Mepartricin Used to treat chronic pelvic pain syndrome, reduces estrogen plasmatic levels and their concentration
in the prostrate. Antifungal activity against Candida infections.
[65,66]
Suloctidil Used as a peripheral vasodilator, formerly in treating peripheral and cerebral vascular disorders; causes
hepatotoxicity.
[67]
doi:10.1371/journal.pone.0007025.t001
Figure 3. Flow chart representing the C. elegans ‘‘curing’’ assay
that identified 19 effective compounds.
doi:10.1371/journal.pone.0007025.g003
Antifungal Bioactive Compounds
PLoS ONE | www.plosone.org 5 September 2009 | Volume 4 | Issue 9 | e7025MIC values may fluctuate from previously published reports,
possibly due to differences in the liquid media used for each of the
assays and in particular the time at which the cultures are
monitored (two days in the established Clinical and Laboratory
Standards Institute (CLSI) protocol for MIC determination versus
five days in this assay). However, the standard antifungal used for
optimization of the assay amphothericin B had an MIC value of
1.0 mg/mL, which is within the published range of 0.5–2.0 mg/mL
[41].
Previously, three compounds were identified which prolonged
nematode survival when infected with C. albicans [6]. Two of these
compounds, caffeic acid phenethyl ester (CAPE) and enoxacin,
also displayed antifungal activity when carried over into a murine
model. However, of these two compounds only CAPE was able to
inhibit C. albicans growth in vitro. The MIC of CAPE was 64 mg/
mL, well above the 4 mg/mL concentration which was required to
observe an increase in C. elegans survival [6], suggesting the
compound maybe involved in a role besides inhibition of fungal
growth, and thus conferring the observed increase in C. elegans
survival. A similar trend was observed in a C. elegans-Enterococcus
faecalis antibacterial drug discovery screen, where six classes of
compounds displayed effective concentrations lower than the MIC
[18]. Therefore, comparison to the MIC and the EC50 in the C.
elegans assay may be used to identify compounds that have higher
efficacy during infection than in vitro, as such compounds may
affect virulence factors or modulate host immunity. Compounds
that may fall into this class are often not identified in a traditional
antifungal compound screen as the screen may rely solely on
inhibiting microbial growth. Although the concentration of the
compounds inside the nematode is probably lower than in the
media, the ratio between the MIC and the EC50 provides a way to
identify compounds that most likely have a higher efficacy in vivo
than in vitro.
Evaluation of compound toxicity
This screen also allowed simultaneous assessment of the
compound’s toxicity, as a decrease in nematode survival at higher
compound concentrations despite no evidence of fungal growth in
vitro or filamentation in vivo was an indication that the compound
was toxic to the worm. In addition to the MIC and EC50 values,
the dose-response experiments also detected toxic compounds such
as malachite green carbinol base which is the carbinol form of
malachite green, usually metabolized to the toxic leucomalachite
green form [42]. In the initial portion of the curve, there was no
worm survival up to a concentration of 0.95 mg/ml, and there
were visible C. albicans filaments on dead worms. At concentrations
greater than 0.95 mg/mL up to the EC50 concentration (7.62 mg/
mL), worm survival increased, however at concentrations higher
than the EC50 there was no survival of any worms (Figure 5). This
was probably due to the toxic effect of the compound since in vitro
growth of C. albicans in the wells was absent, and in vivo activity of
the compound within the worms did not permit formation of C.
albicans filaments penetrating from the cuticle into the surrounding
medium.
Concluding remarks
A high-throughput whole animal assay for the identification of
compounds with antifungal efficacy has been developed using C.
elegans as a heterologous host. The major developments include the
use of the worm-dispensing instrument, the use of a standardized
fungal inoculum, and the advance of using a co-inoculation
procedure of Candida and C. elegans to the wells, thereby eliminating
the labor-intensive infection. This facile in vivo model can now be
used in high-throughput assays to evaluate large libraries of
chemical compounds and avoid some of the main obstacles in
current antifungal discovery, including host toxicity screening,
costs, and time.
Table 2. Minimal inhibitory concentrations (MIC) in vitro and effective concentration (EC50) in vivo of compounds identified in the
C.elegans-C. albicans screen.
Compounds MIC in vitro (mg/mL) MIC in literature for C. albicans EC50 in vivo (mg/mL)
Amphotericin B 1.0 0.25–2.0 [41,68] 2.0
Nystatin 4.5 17.8
Ketoconazole 4.4 0.12–16 [68] 8.9
Terconazole 0.06 0.11
Bifonazole 19.0 3.60* [50] 26.0
Butoconazole nitrate 0.6 8.0* [53] 1.1
Oxiconazole nitrate 4.7 9.4
Triadimefon 6.5 9.2
Dequalinium chloride 4.4 7.1
Valinomycin 12.2 0.49–62.5* [60] 24.4
Phenylmercuric acetate 7.4 14.8
Malachite green carbinol base 3.8 7.6
Ascomycin 14.6 29.3
FK-506 (Tacrolimus) 72.0 .3.12 [34] 72.0
Cyclosporin A 53.0 .12.5 [34] 105.8
Concanamycin A 1.7 .100* [40] 2.1
Mepartricin 12.6 0.18* [66] 25.1
Suloctidil 11.7 17.4
*The MIC was determined using a procedure other than the standard CLSI protocol.
doi:10.1371/journal.pone.0007025.t002
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estimated at $1 billion per year [43], while the average cost of
treating a single episode of candidemia is $34,123–44,536 (1997
U.S. dollars) [44]. Further complicating issues in treatment of
candidemia is the emergence of drug resistant isolates. While
most attention has been focused on antibacterial drug
resistance, a similar phenomenon has occurred with fungi due
to long term use of antifungal agents, particularly in patients
who require these medications for the duration of their lives (eg.
HIV positive patients, organ transplant recipients). Drug
resistant C. albicans isolates have been isolated from patients
which are resistant to the most recent class of antifungal
compounds developed, the echinocandins [45], further high-
lighting the need for antifungal drug development [46]. The
discovery of new antifungal agents may be a daunting but
certainly crucial task.
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